Worth reading
67In focus
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
699
¥100 million (year-on-year increase in revenue)Wording
Conditional
How definitive the wording is.Contents of this document
Results presentationFY2026 Second Quarter (First Half)9 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales4,700 Hundreds of millions of yen+17.5%
Operating profit414 Hundreds of millions of yen+20.4%
Net income¥299 100 million +21.5%attributable to owners of the parent
Selling, general and administrative expenses2,352 Hundreds of millions of yen
Operating profit margin8.8%, up 0.2 percentage points year on year
Full-year earnings forecast
Revenue
8,835 Hundreds of millions of yen
Operating profit
700 Hundreds of millions of yen
Profit attributable to owners of the parent
523 Hundreds of millions of yen
Interim (current-period) profit
540 Hundreds of millions of yen
Pharmaceutical business revenue
8,700 Hundreds of millions of yen
Other businesses revenue
135 Hundreds of millions of yen
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Revenue53.2%
Pharmaceutical business revenue53.1%
Other businesses revenue58.6%
Operating profit59.2%
Core operating profit61.5%
Profit attributable to owners of the parent57.2%
By pharmaceutical business segmentJapan 50.0%, Americas 53.2%, China 56.2%, EMEA 59.8%, EAGS 50.1%
Core products3L total 52.6%, Lenvima 56.5%, Leqembi 42.9%, Dayvigo 53.8%
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Progress exceeding planBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Revenue3L +¥59.1 billion, products other than 3L +¥9.7 billion, Other businesses +¥1.2 billion
Operating profitGross profit +¥53.5 billion, research and development expenses -¥12.6 billion, selling and administrative expenses -¥31.2 billion, other income and expenses -¥2.7 billion
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
US dollar¥153.00
EuroJPY 180.00
British pound¥205.00
Renminbi¥22.50/CNY
New initiatives
- Market launch of the Leqembi subcutaneous auto-injector formulation (SC-AI) in the United States, Japan and other markets
- U.S. approval and Japanese application for the combination therapy of Lenvima and Welireg
- Continued clinical development of preclinical AD, etalanetug, ledasorexton and other projects
Key KPIsA metric the company considers important as a management benchmark.
- EPS106.18 YenYear on year against the same period last year+21.5%
- 3L revenue2,958 Hundreds of millions of yenYear on year against the same period last year+24.9%
- Lenvima revenue1,948 Hundreds of millions of yenYear on year against the same period last year+17.0%
- Leqembi revenue615 Hundreds of millions of yenYear on year against the same period last year+49.7%
- Dayvigo revenue395 Hundreds of millions of yenYear on year against the same period last year+35.7%
Unit price and quantity metricsThese figures show sales broken down by price and volume.
Six-month average growth rate in prescription volume: Lenvima total 6.9%, renal cell carcinoma 8.6%, endometrial cancer 6.3%, thyroid cancer 4.6%, hepatocellular carcinoma 7.9%Segment results
Pharmaceutical Business
Revenue¥462.1 billion, up 17.5% year on year
Segment profit¥140.2 billion, up 29.0% year on year
Japan pharmaceutical business
Revenue¥116.7 billion, up 3.7% year on year
Segment profit¥36.6 billion, up 8.9% year on year
Americas pharmaceutical business
Revenue¥179.2 billion, up 26.5% year on year
Segment profit¥46.6 billion, up 55.6% year on year
China pharmaceutical business
Revenue¥82.6 billion, up 24.7% year on year
Segment profit¥32.9 billion, up 25.1% year on year
EMEA pharmaceutical business
Revenue¥43.7 billion, up 12.6% year on year
Segment profit¥10.1 billion, up 59.0% year on year
EAGS pharmaceutical business
Revenue¥39.9 billion, up 17.0% year on year
Segment profit¥14.1 billion, up 12.4% year on year
Other businesses
Revenue¥7.9 billion, up 17.2% year on year
Segment profit¥2.5 billion, down 19.2% year on year
Market Size / Share
Lenvima has the leading market share in multiple cancer types and treatment categories in the United States. Dayvigo holds the No. 1 share in Japan in both sales and the number of patients treated. IQLIK is scheduled for inclusion in U.S. Medicare Part D in January 2027 and has secured coverage for approximately 67% of the enrollee base.Gross profit
77.7%, down 0.3 percentage points year on year| Item | Details |
|---|---|
| Document type | Results presentation |
| Fiscal Period Covered | FY2026 Second Quarter (First Half) |
| Net Sales | 4,700 Hundreds of millions of yen (YoY +17.5%) |
| Operating profit | 414 Hundreds of millions of yen (YoY +20.4%) |
| Net income | ¥299 100 million (attributable to owners of the parent) (YoY +21.5%) |
| Gross profit | 77.7%, down 0.3 percentage points year on year |
| Operating profit margin | 8.8%, up 0.2 percentage points year on year |
| Selling, general and administrative expenses | 2,352 Hundreds of millions of yen |
| Full-year earnings forecast | Revenue 8,835 Hundreds of millions of yen / Operating profit 700 Hundreds of millions of yen / Profit attributable to owners of the parent 523 Hundreds of millions of yen / Interim (current-period) profit 540 Hundreds of millions of yen / Pharmaceutical business revenue 8,700 Hundreds of millions of yen / Other businesses revenue 135 Hundreds of millions of yen |
| Progress against full-year forecast | Revenue 53.2% / Pharmaceutical business revenue 53.1% / Other businesses revenue 58.6% / Operating profit 59.2% / Core operating profit 61.5% / Profit attributable to owners of the parent 57.2% / By pharmaceutical business segment Japan 50.0%, Americas 53.2%, China 56.2%, EMEA 59.8%, EAGS 50.1% / Core products 3L total 52.6%, Lenvima 56.5%, Leqembi 42.9%, Dayvigo 53.8% |
| Self-assessment against the plan | Progress exceeding plan |
| Segment results | Pharmaceutical Business Revenue ¥462.1 billion, up 17.5% year on year / Segment profit ¥140.2 billion, up 29.0% year on year / Japan pharmaceutical business Revenue ¥116.7 billion, up 3.7% year on year / Segment profit ¥36.6 billion, up 8.9% year on year / Americas pharmaceutical business Revenue ¥179.2 billion, up 26.5% year on year / Segment profit ¥46.6 billion, up 55.6% year on year / China pharmaceutical business Revenue ¥82.6 billion, up 24.7% year on year / Segment profit ¥32.9 billion, up 25.1% year on year / EMEA pharmaceutical business Revenue ¥43.7 billion, up 12.6% year on year / Segment profit ¥10.1 billion, up 59.0% year on year / EAGS pharmaceutical business Revenue ¥39.9 billion, up 17.0% year on year / Segment profit ¥14.1 billion, up 12.4% year on year / Other businesses Revenue ¥7.9 billion, up 17.2% year on year / Segment profit ¥2.5 billion, down 19.2% year on year |
| Breakdown of Factors Affecting the Change | Revenue 3L +¥59.1 billion, products other than 3L +¥9.7 billion, Other businesses +¥1.2 billion / Operating profit Gross profit +¥53.5 billion, research and development expenses -¥12.6 billion, selling and administrative expenses -¥31.2 billion, other income and expenses -¥2.7 billion |
| Key KPIs | 106.18 Yen, 2,958 Hundreds of millions of yen, 1,948 Hundreds of millions of yen, 615 Hundreds of millions of yen, 395 Hundreds of millions of yen |
| Unit price and quantity metrics | Six-month average growth rate in prescription volume: Lenvima total 6.9%, renal cell carcinoma 8.6%, endometrial cancer 6.3%, thyroid cancer 4.6%, hepatocellular carcinoma 7.9% |
| Assumptions Underlying the Business Outlook | US dollar ¥153.00 / Euro JPY 180.00 / British pound ¥205.00 / Renminbi ¥22.50/CNY |
| Market Size / Share | Lenvima has the leading market share in multiple cancer types and treatment categories in the United States. Dayvigo holds the No. 1 share in Japan in both sales and the number of patients treated. IQLIK is scheduled for inclusion in U.S. Medicare Part D in January 2027 and has secured coverage for approximately 67% of the enrollee base. |
| New initiatives | Market launch of the Leqembi subcutaneous auto-injector formulation (SC-AI) in the United States, Japan and other markets, U.S. approval and Japanese application for the combination therapy of Lenvima and Welireg, Continued clinical development of preclinical AD, etalanetug, ledasorexton and other projects |
Items this document does not state (13)
Ordinary incomeResults for the three months of the current quarterNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Growth in the three main products, particularly the substantial growth of the Pharmaceuticals business, drove higher revenue and profit. For operating profit, the increase in gross profit exceeded the deterioration in research and development expenses, selling, general and administrative expenses, and other income and expenses.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.